HomeNewsBusinessMarketsDAILY VOICE | COVID helped us sharpen investing framework and made us agile: Sharad Pachisiya of SageOne Investment Advisors

DAILY VOICE | COVID helped us sharpen investing framework and made us agile: Sharad Pachisiya of SageOne Investment Advisors

At SageOne, we always strive to build and maintain a portfolio of superior businesses with high earnings growth (20%+ CAGR) available at a cheap or fair valuation.

October 12, 2020 / 15:51 IST
Story continues below Advertisement

We continue to stick to our investment philosophy to invest in superior and reasonably-valued businesses and hold them till the business fundamentals confirm to our thesis, Sharad Pachisiya, CEO at SageOne Investment Advisors LLP, said in an interview with Moneycontrol’s Kshitij Anand.

Edited excerpts:
Q) Latest microdata suggests some green shoots. What are your views?

A) After a dismal micro-data in the last 2 quarters owing to the COVID-19 impact, the Q2 FY21 micro-data (high-frequency indicators like auto sales, freight traffic, GST collections, & capacity utilisation) has given some positive indication that the economy activity is trying to come back in pockets.

Story continues below Advertisement

However, the credit environment and offtake is yet to see some encouraging signs which is the backbone of the economy.

Unless the credit offtake improves, it is difficult to extrapolate the economy's normalcy and growth. From an investment perspective, one should stick to owning quality businesses that are less correlated to the economy, become all the more stronger, larger, and resilient in COVID times.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show